News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Out of Pocket Costs Associated with Biosimilar Use

The panel discusses out of pocket costs and the impact of the 340b program for various patient types.

Episodes in this series

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

A panel of 4 experts on biosimilars

EP. 7 Private Label Biosimilars

EP. 8 Biosimilars in the Commercial Sector

EP. 8 Biosimilars in the Commercial Sector

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 11 Unmet Needs and Future Initiatives

EP. 11 Unmet Needs and Future Initiatives

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 13 Foreseeable Biosimilar Trends

EP. 13 Foreseeable Biosimilar Trends

EP. 14 Legislative Support for Biosimilars

EP. 14 Legislative Support for Biosimilars

EP. 15 Key Takeaways for Biosimilar Utilization

EP. 15 Key Takeaways for Biosimilar Utilization

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

4 Experts are featured in this series

Switching Therapies, Managing Adverse Effects, and Adherence Challenges

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 29th 2025

4 Experts are featured in this series

First- and Second-Generation Antipsychotic Therapies and Treatment Sequencing

ByGus Alva, MD, DFAPA,Rishi Kakar, MD,Philip Harvey, MD,Gerald Maguire, MD

December 29th 2025

4 experts are featured in this series.

Linvoseltamab for Relapsed/Refractory Multiple Myeloma

ByRyan Haumschild, PharmD, MS, MBA,Shahrier Hossain, PharmD,Michael Singel, PharmD,Naresh Bumma, MD

December 29th 2025

4 experts are featured in this series.

CAR-T Scheduling and the Role of Combination Therapy

ByRyan Haumschild, PharmD, MS, MBA,Shahrier Hossain, PharmD,Michael Singel, PharmD,Naresh Bumma, MD

December 29th 2025

Unmet Needs and the Future of Desmoid Tumor Management

ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D

December 23rd 2025

Trending on AJMC

Top 5 Most-Read HIV Articles of 2025

Meta-Analysis Supports RSV Vaccine Efficacy and Safety in Older Adults

Sleep Apnea Risk Tied to 40% Higher Odds of Poor Mental Health

The Top 5 Most-Read Multiple Myeloma Content of 2025

New Evidence Shows Exercise Could Ease Key Symptoms of Ovarian Cancer

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.